Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt (RIG2) - Cash Flow Conversion Efficiency

Latest as of June 2025: 0.040x

Based on the latest financial reports, Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt (RIG2) has a cash flow conversion efficiency ratio of 0.040x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€52.44 Billion ≈ $61.30 Billion USD) by net assets (€1.30 Trillion ≈ $1.52 Trillion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Richter Gedeon Vegyészeti Gyár Nyilvános to measure how much of total assets are equity-financed.

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt - Cash Flow Conversion Efficiency Trend (2013–2025)

This chart illustrates how Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check RIG2 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Lotes Co Ltd
TW:3533
0.037x
Wallenius Wilhelmsen Logistics ASA
OL:WAWI
0.135x
Chime Financial, Inc. Class A Common Stock
NASDAQ:CHYM
0.061x
Lumen Technologies Inc
NYSE:LUMN
0.114x
Informatica Inc
NYSE:INFA
0.061x
The Swatch Group AG
SW:UHR
0.028x
Nkt A/S
NYSE:NRKBY
0.025x
Jindal Stainless Limited
NSE:JSL
0.110x

Annual Cash Flow Conversion Efficiency for Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt (2013–2025)

The table below shows the annual cash flow conversion efficiency of Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see Richter Gedeon Vegyészeti Gyár Nyilvános market cap and net worth.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 €1.40 Trillion
≈ $1.64 Trillion
€276.40 Billion
≈ $323.14 Billion
0.197x -7.91%
2024-12-31 €1.30 Trillion
≈ $1.52 Trillion
€279.37 Billion
≈ $326.61 Billion
0.214x +67.87%
2023-12-31 €1.14 Trillion
≈ $1.34 Trillion
€145.84 Billion
≈ $170.50 Billion
0.128x -26.81%
2022-12-31 €1.06 Trillion
≈ $1.24 Trillion
€184.93 Billion
≈ $216.20 Billion
0.174x +15.06%
2021-12-31 €923.02 Billion
≈ $1.08 Trillion
€139.90 Billion
≈ $163.56 Billion
0.152x -7.60%
2020-12-31 €813.94 Billion
≈ $951.58 Billion
€133.52 Billion
≈ $156.10 Billion
0.164x +21.07%
2019-12-31 €724.87 Billion
≈ $847.45 Billion
€98.21 Billion
≈ $114.82 Billion
0.135x -7.41%
2018-12-31 €685.75 Billion
≈ $801.71 Billion
€100.34 Billion
≈ $117.31 Billion
0.146x +16.02%
2017-12-31 €664.02 Billion
≈ $776.31 Billion
€83.75 Billion
≈ $97.91 Billion
0.126x +11.08%
2016-12-31 €681.87 Billion
≈ $797.18 Billion
€77.42 Billion
≈ $90.51 Billion
0.114x -26.13%
2015-12-31 €618.39 Billion
≈ $722.96 Billion
€95.05 Billion
≈ $111.12 Billion
0.154x +38.81%
2014-12-31 €561.73 Billion
≈ $656.72 Billion
€62.20 Billion
≈ $72.72 Billion
0.111x -17.46%
2013-12-31 €551.20 Billion
≈ $644.41 Billion
€73.94 Billion
≈ $86.45 Billion
0.134x --

About Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt

F:RIG2 Germany Drug Manufacturers - Specialty & Generic
Market Cap
$7.06 Billion
€6.04 Billion EUR
Market Cap Rank
#2970 Global
#583 in Germany
Share Price
€33.12
Change (1 day)
+3.24%
52-Week Range
€24.60 - €36.66
All Time High
€36.66
About

Gedeon Richter PLC researches, develops, manufactures, markets, and sells pharmaceutical products. It offers women's healthcare products for contraceptives, endometriosis, fertility, menopause, vaginal infections, and uterine fibroids; and Femtech, a digital therapeutic solution to enhance women's lives. It also provides central nervous system products, such as products for the treatment of chron… Read more